Leah Kuntz

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Lawsuits, research, and clinicians clash over youth screen addiction—learn more about how problematic social platform use evades diagnosis and how we can curb harm.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

Explore Pride Month insights on LGBTQ+ and other minoritized patients—social determinants, research, practice tips, and case studies for clinicians, in our June theme.

Check out the pipeline updates from May!

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.

New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.

Synendos launches a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety symptoms with improved safety and adherence.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.

Study ties higher schizophrenia rates in Black Americans to neighborhood vulnerability, spotlighting faster early-psychosis care and social supports.

Phase 2 MINDFuL data show XPro trends toward cognitive and biomarker gains in inflammation-defined mild Alzheimer disease, with no ARIA, guiding phase 3 plans.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

A new report shows private practice clinicians deliver over 113 million sessions of mental health care, making up the majority of outpatient care.

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

Leading psychiatric organizations respond to federal push for deprescribing.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

Check out the pipeline updates from April!

The FDA has approved Auvelity, an oral NMDA/sigma-1 therapy, offering a new option to curb Alzheimer disease agitation and ease caregiver burden.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.

AXS-05 for Alzheimer disease agitation nears FDA decision date.

How do estrogen, testosterone, and aromatase shape binge eating and bulimia risk? Let's explore brain biomarkers and future hormone-aware treatments.

AFSP and JED plan a 2026 merger to form the largest US suicide prevention nonprofit, uniting research, youth mental health programs, advocacy, and community support.

Two-dose oral R‑MDMA, EMP-01, cuts social anxiety symptoms and real‑world avoidance in phase 2a study, with strong responder rates and good tolerability.